17 Sep 2025 | 5 Mins Read
Biocon Biologics receives US FDA approval for osteoporosis treatments
Flipitmoney
Biocon Biologics Ltd's subsidiary received US FDA approvals for Bosaya (Prolia biosimilar) and Aukelso (Xgeva biosimilar). Both products received provisional interchangeability designation allowing pharmacy-level substitution. The approvals expand Biocon's oncology and bone health portfolio, offering more affordable treatment options with denosumab sales reaching nearly $5 billion.